

Special Issue

New Insights in Parotid Tumors

Message from the Guest Editors

The treatment of malignant parotid tumors is challenging due to the rarity and heterogeneity of this disease and the complexity of the anatomy. Therefore, recent recommendations regarding the surgical management of this disease enable both the primary tumor and neck lymph nodes to be managed in different ways, such as in low- and high-grade tumors. In higher staged malignant tumors, neoadjuvant or adjuvant chemotherapy and radiotherapy may be required. This could include the integration of modern forms of photon therapy, brachytherapy, particle therapies and radionuclides alongside the development of novel systemic drug therapies in both adjuvant and definitive treatment programs. This Special Issue will provide novel insights into the diagnosis and preoperative evaluation of parotid tumors with the aid of advanced imaging techniques and artificial intelligence tools, the application of surgical techniques and reconstruction methods, and the utilization of neoadjuvant and adjuvant therapeutic techniques that improve outcomes in these patients.

Guest Editors

Dr. Chiara Gaudino

Department of Neuroradiology, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy

Prof. Dr. Stefan Rohde

Department of Radiology and Neuroradiology, Klinikum Dortmund gGmbH, Dortmund, Germany

Deadline for manuscript submissions

31 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/236824

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)